治験レーダーAI | ||
|---|---|---|
治験 NCT00232583(対象:2型糖尿病)は完了です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus 58
治験(臨床試験)の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします!「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT00232583 は 介入研究 臨床試験 で、2型糖尿病 を対象とした研究でした。現在は 完了 です。2003年11月1日 に開始し、58 名の参加者 が参加しました。この試験は テキサス大学南西部医学センター によって主導され、2011年12月1日 に完了しました。ClinicalTrials.gov からの最新更新日は 2017年12月14日 です。
概要
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
詳細説明
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
公式タイトル
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
疾患名
2型糖尿病刊行物
この臨床試験について発表された科学記事と研究論文:その他の研究識別子
- 1003-623
NCT番号
開始日
2003-11
最終更新日
2017-12-14
終了予定日
2011-12
目標参加者数
58
試験の種類
介入研究
治験の相・段階
該当なし
状況
完了
キーワード
TYpe 2 diabetes mellitus
Newly diagnosed
Beta-cell function
Newly diagnosed
Beta-cell function
主目的
治療
割付方法
無作為化
介入モデル
並行割当
盲検化
なし(非盲検)
群(アーム)/介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実薬対照薬Metfomin and Insulin Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration | メトホルミン Metformin 1000mg/BID インスリン Insulin Novolg 70/30 per protocol titration |
実薬対照薬Metformin, Pioglitazone and Glyburide Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration | Metfomin Metformin 1000mg/BID Pioglitazone Pioglitazone 45mg glyburide Glyburide per protocol titration |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Beta-cell Function - C-peptide AUC (Area Under the Curve) | C-peptide AUC during a 3-hours mixed meal challenge testing | 72 months |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Insulin Sensitivity as Measure be Matsuda Index | C-peptide-based Matsuda index using following formula: Matsuda index = 500,00 / root square \[(fasting c-peptide x fasting glucose x 333) x (average c-peptide 0-120 mins x average glucose 0-120 mins x 333). Higher the Matsuda index, better the insulin sensitivity. | 72 months |
Bet-cell Function Measured by Disposition Index | Disposition index was measured by multiplying the insulin secretion (C-peptide AUC/C-peptide AUC glucose) by the Matsuda index. Disposition index reflects the beta-cell function adjusted for total body insulin sensitivity | 72 months |
Weight | Body Weight | 72 months |
Inflammatory Markers - hsCRP | Inflammatory markers - hsCRP (C reactive protein) | 72 months |
Inflammatory Markers -Fibrinogen | Inflammatory markers - Fibrinogen | 72 months |
Inflammatory Markers - PAI-1 | Inflammatory markers - PAI-1 (Plasminogen activator inhibitor type 1) | 72 months |
Quality of Life Survey (QoL) - Current Health Perception | Current health perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago. | 72 months |
Quality of Life Survey (QoL) - Treatment Satisfaction | Treatment satisfaction was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied. | 72 months |
Quality of Life Survey (QoL) - Treatment Impact | Treatment impact was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied. | 72 months |
Quality of Life Survey (QoL) - Social or Vocational Worry | Social or vocational worry was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time. | 72 months |
Quality of Life Survey (QoL) - Hypoglycemia Fear | Hypoglycemia fear was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry | 72 months |
Quality of Life Survey (QoL) - Glycemia Control Perception | Glycemia control perception was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled. | 72 months |
Quality of Life Survey (QoL) - Lifestyle Flexibility | Lifestyle flexibility was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice. | 72 months |
Quality of Life Survey (QoL) - Social Stigma | Social stigma was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1- strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree. | 72 months |
Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment | Satisfaction with insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied. | 72 months |
Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment | Willingness to continue insulin treatment was measured at randomization and 72 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing. | 72 months |
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
25 Years
対象性別
全て
- type 2 diabetes mellitus diagnosed within the prior 2 months
- HbA1c > 7% at the time of inclusion
- willing to perform intensive diabetes management
- able to comply with treatment and follow-up regimen
- HbA1c > 8% at time of randomization
- creatinine > 1.5 mg/dl
- liver function tests > 3 times the upper limit of normal
- severe anemia
- severe proliferative retinopathy
- NYHA class III or IV heart failure
- active CAD or recent (within 6 months) MI
- pregnant, willing to get pregnant, or not willing to practice any contraceptive method
- non-english speaking
- active heavy alcohol or illicit drug users (within past 6 months)
- history of lactic acidosis
責任者
Ildiko Lingvay, 主任研究者, MD, MPH, MSCS, University of Texas Southwestern Medical Center
連絡先情報がありません。
1 1カ国の場所
Texas
University of Texas Southwestern, Dallas, Texas, 75390, United States